Scope Fluidics SA (SCP) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.102x

Based on the latest financial reports, Scope Fluidics SA (SCP) has a cash flow conversion efficiency ratio of -0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.75 Million ≈ $-3.23 Million USD) by net assets (zł115.43 Million ≈ $31.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scope Fluidics SA market cap and net worth for the company's overall valuation and market capitalisation.

Scope Fluidics SA - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Scope Fluidics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Scope Fluidics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scope Fluidics SA ranked by their cash flow conversion efficiency. Explore SCP cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
CGRE AG
XETRA:CGX
N/A
Evergreen Max Cash Capital Berhad
KLSE:0286
-0.215x
RiTdisplay Corp
TW:8104
0.022x
Euroapi SAS
PA:EAPI
-0.091x
Chernan Metal Industrial
TWO:3631
0.004x
ANDRADA MINING LTD.
F:9IA
N/A
Positivo Tecnologia S.A
SA:POSI3
0.073x
Beazley plc
LSE:BEZ
0.050x

Annual Cash Flow Conversion Efficiency for Scope Fluidics SA (2015–2024)

The table below shows the annual cash flow conversion efficiency of Scope Fluidics SA from 2015 to 2024. View SCP stock price and chart for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł146.35 Million
≈ $40.28 Million
zł-25.10 Million
≈ $-6.91 Million
-0.172x +27.15%
2023-12-31 zł80.93 Million
≈ $22.27 Million
zł-19.06 Million
≈ $-5.24 Million
-0.235x -178.45%
2022-12-31 zł332.97 Million
≈ $91.64 Million
zł-28.16 Million
≈ $-7.75 Million
-0.085x +94.44%
2021-12-31 zł14.58 Million
≈ $4.01 Million
zł-22.19 Million
≈ $-6.11 Million
-1.522x -215.52%
2020-12-31 zł33.09 Million
≈ $9.11 Million
zł-15.96 Million
≈ $-4.39 Million
-0.482x +6.93%
2019-12-31 zł20.22 Million
≈ $5.56 Million
zł-10.48 Million
≈ $-2.88 Million
-0.518x -23.38%
2018-12-31 zł12.81 Million
≈ $3.52 Million
zł-5.38 Million
≈ $-1.48 Million
-0.420x -43.76%
2017-12-31 zł16.88 Million
≈ $4.64 Million
zł-4.93 Million
≈ $-1.36 Million
-0.292x +57.84%
2016-12-31 zł5.58 Million
≈ $1.53 Million
zł-3.87 Million
≈ $-1.06 Million
-0.693x -966.74%
2015-12-31 zł6.70 Million
≈ $1.84 Million
zł535.69K
≈ $147.43K
0.080x --

About Scope Fluidics SA

WAR:SCP Poland Diagnostics & Research
Market Cap
$94.68 Million
zł344.01 Million PLN
Market Cap Rank
#19465 Global
#153 in Poland
Share Price
zł126.20
Change (1 day)
-2.17%
52-Week Range
zł113.00 - zł180.80
All Time High
zł341.00
About

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.